Navigation Links
Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Date:3/3/2008

SEATTLE, March 3 /PRNewswire-FirstCall/-- Dendreon Corporation (Nasdaq: DNDN) announced the publication of a manuscript titled, "CD54 is a surrogate marker of antigen presenting cell activation" in Cancer Immunology, Immunotherapy.

The manuscript describes and supports the use of CD54 as a surrogate marker of antigen presenting cell activation (APC) activation and validates its utility as a potency measure of PROVENGE(R) (sipuleucel-T). In particular, it describes how Dendreon researchers used CD54 and the upregulation of its expression on antigen presenting cells (APC) as a means by which human APC activation could be assessed and most importantly, how such measurements could be used to determine the potency of PROVENGE before its administration to patients with prostate cancer. The assessment of product potency is a key release measure required by the U.S. Food and Drug Administration (FDA).

The upregulation of CD54 has been used as part of the potency assay for PROVENGE since the initiation of the PROVENGE clinical development program. Data correlating CD54 upregulation to overall survival in patients from two Phase 3 trials, D9901 and D9902A have been presented at recent scientific meetings and at the FDA Cell Tissue and Gene Therapy Advisory Committee Meeting on March 29, 2007.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
9. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
10. Consortium publishes Phase II map of human genetic variation
11. The Lancet Publishes Vasogens ACCLAIM Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... new alliance will see the two universities and NPL ... with business and industry and their complementary academic strengths., ... help to shape the scientific priorities of the UK. ... up to 300 high-calibre PhD students, will provide a ... NPL, the potential of the Laboratory will be grown ...
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group of ... teaming up with the Heartland Blood Center and offering free ... The drive takes place Saturday, Jan. 18 at the Bill ... p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... Hills, IL (PRWEB) January 15, 2014 ... to find hard-working items for the lab, from fluid ... as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model for ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
Breaking Biology Technology:Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... , CALGARY and CAMBRIDGE, MA , ... leading developer of biosimilar drug candidates, high-value proteins and oils ... Rick Pierce has joined the Company as President of ... office in Cambridge, Massachusetts which will offer the ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical ... into a purchase agreement to sell $3.9 million of its ... public offering.   , , ... the terms of the purchase agreement, PharmAthene will sell an aggregate of ...
... 20, 2010 Today at the XVIII International AIDS ... Microbicide Advocates (IRMA) and thousands of other HIV advocates ... the quest for new HIV prevention technologies. Researchers announced ... reduce a woman,s risk of being infected with HIV ...
Cached Biology Technology:SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 2SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 3SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 4PharmAthene Announces $3.9 Million Registered Direct Offering 2PharmAthene Announces $3.9 Million Registered Direct Offering 3HIV prevention science scores a victory -- the gel works! 2HIV prevention science scores a victory -- the gel works! 3
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
(Date:7/10/2014)... the main organization of the International Science and Business ... group of researchers, led by professor Won Do Heo, ... optogenetics that can remotely control specific receptors by light. ... has succeeded with neuronal differentiation inducement. , The most ... only light to activate neuronal functions without the need ...
(Date:7/10/2014)... oil found in your popcorn or soap might not be ... worse, according to an analysis in the Cell Press journal ... demand for vegetable oil has already led to the conversion ... for orangutans in particular. If guidelines are not put in ... industrial plantations from Asia into Africa will be bad news ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2
... 3, 2008) According to a report released today ... rare waterbirds from Cambodias famed Tonle Sap region have ... single team of park rangers to provide 24-hour protection ... employing former hunters and egg collectors to protect and ...
... Continuous oral contraceptives may be more effective than the ... according to researchers. They say that the continuous pill ... changes. "We have provided a biological proof of concept ... uterus are suppressed better and quicker with the continuous ...
... a new technique for turning embryonic stem cells into ... breakthrough in the quest to find new treatments for ... colleagues at the University of Sheffield, were able to ... an important protein known as a transcription factor. ...
Cached Biology News:Continuous oral contraceptives better at easing pain, bleeding 2Continuous oral contraceptives better at easing pain, bleeding 3Stem cell breakthrough offers diabetes hope 2
... Instrument System is ideal for developing ... Beadlyte reagents. The Luminex 100 Instrument ... software version 1.7, the XY platform ... offers $2000 in free Beadlyte products ...
Polyclonal Antibody to HADHB...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: